Konica Minolta Precision Medicine Japan

Konica Minolta Precision Medicine Japan, Inc. (KMPMJ) — Konica Minolta branch in Japan on development of solutions in the field of exact medicine.

As of October, 2018 it is planned that:

• Will provide to representatives of the pharmaceutical industry and scientific community KMPMJ individual services for optimization and acceleration of promotion of research work thanks to identification, quantitative analysis and detection of biomarkers, characteristic of a disease;
• Will offer the medical organizations KMPMJ services of genetic diagnostics, molecular marking and analytics;
• The researchers analyzing different biological information from different sources will be able to use KMPMJ services in the field of bioinformation science on the basis of the saved-up data;
• KMPMJ will also offer services of search of patients with certain molecular biomarkers for participation in the clinical trials conducted by scientific community and the biopharmaceutical industry.

History

2018: Creation of the company

The Konica Minolta company announced on October 25, 2018 opening of branch Konica Minolta Precision Medicine Japan, Inc. (KMPMJ) which will focus on development of tools of exact medicine and rendering diagnostic services in Japan. 100% of stocks of KMPMJ belong to Konica Minolta.

The office of the newly opened company is located in Tokyo. 23 persons will work in it. Ken Masuo, in the past the chief executive on marketing with more than 30-year work experience in the pharmaceutical industry became the president of KMPMJ.

Konica Minolta opened in Japan branch on development of solutions in the field of exact medicine

It is supposed that KMPMJ will develop and offer tools for identification and tracking of biomarkers, characteristic of certain diseases (indicators of problems with genes and proteins and also certain statuses of the person) and the related services allowing to accelerate development of methods of the directed therapy. It will also render services of diagnostic and predictive testing on the basis of a research of genes, proteins and molecules which will expand the existing possibilities of medicine in the field of diagnostics and treatment of patients.

According to representatives of Konica Minolta, opening of KMPMJ branch — a part of strategy of Konica Minolta on transformation of the personalized medicine. So, in 2017 Konica Minolta purchased Ambry Genetics Corporation (Ambry), the American company working in a segment of genetic researches and diagnostics and also Invicro, the service company promoting search and creation of the latest types of drugs at the expense of tools of artificial intelligence. Earlier Konica Minolta started the direction of exact medicine on the basis of own developments in the field of medical visualization and technology of immune coloring — High-Sensitivity Tissue Testing (HSTT) which uses fluorescent nanoparticles for quantitative determination of the proteins leading to diseases. Combining solutions and experience of three companies, KMPMJ expects to propose the standardized and integrated solutions for all fields of transmitting medicine, necessary for modern health care.

We will be engaged in the analysis at the molecular level and support of process of search and creation of new drugs in Japan — Ken Masuo, the president of KMPMJ told. — For this purpose we will use advanced technology of HSTT from Konica Minolta and also possibilities of Ambry and Invicro. The company will offer high-quality diagnostic services, and it will be our contribution to development and upgrade of medicine. As result, more patients will be able to receive correctly picked up therapy in time.

The exact medicine relies on information on development of a disease in certain groups of people and allows to make decisions on the basis of the analysis of big arrays of information

As you know, the exact medicine relies on information on development of a disease in certain groups of people and allows to make decisions on the basis of the analysis of big arrays of information: data on types of a gene mutation, the therapy choice, level of content of proteins to which maintenance medications, the predicted performance indicators of drugs, data on development and forecasts of a course of diseases are directed.

Thanks to integration of technology platforms of Konica Minolta, Ambry and Invicro the KMPMJ company will be able to render services in the field of medical analytics and detection of diseases at the molecular level. It is expected that these services will promote expansion of the knowledge base about functions of genes and proteins and their communications with diseases of bodies. The company will also get support of all global network of the companies which are engaged in search of drugs and scientific research in which more than 1,000 specialists are engaged.

Konica Minolta took an important step on the way to the digital company working in such socially responsible sphere as health care — the president of Konica Minolta Healthcare considers Kiyotak Fudzhiya. — Thanks to creation of KMPMJ the pharmaceutical companies, research and medical institutes and hospitals will be able to obtain from a uniform source reliable data and services at all stages of researches.